1. Home
  2. ATHA

as 05-24-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Founded: N/A Country:
United States
United States
Employees: N/A City: BOTHELL
Market Cap: 100.4M IPO Year: 2020
Target Price: $19.00 AVG Volume (30 days): 313.0K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.05 EPS Growth: N/A
52 Week Low/High: $1.33 - $4.30 Next Earning Date: 05-15-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Athira Pharma Inc. (ATHA)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Lenington Rachel ATHA Chief Operating Officer Jan 4 '24 Sell $2.91 2,412 $7,018.92 13,395 SEC Form 4
Lenington Rachel ATHA COO AND CDO Jan 4 '24 Sell $2.91 2,412 $7,018.92 13,395 SEC Form 4
Litton Mark James ATHA CEO Jan 4 '24 Sell $2.91 4,820 $14,026.20 144,397 SEC Form 4
Worthington Mark ATHA GENERAL COUNSEL Jan 4 '24 Sell $2.91 2,412 $7,018.92 34,452 SEC Form 4
CHURCH KEVIN ATHA CHIEF SCIENTIFIC OFFICER Jan 4 '24 Sell $2.91 2,412 $7,018.92 80,256 SEC Form 4
Litton Mark James ATHA Chief Executive Officer Jan 4 '24 Sell $2.91 4,820 $14,026.20 144,397 SEC Form 4
Worthington Mark ATHA General Counsel Jan 4 '24 Sell $2.91 2,412 $7,018.92 34,452 SEC Form 4
CHURCH KEVIN ATHA Chief Scientific Officer Jan 4 '24 Sell $2.91 2,412 $7,018.92 80,256 SEC Form 4
PERCEPTIVE ADVISORS LLC ATHA Director10% Owner Dec 27 '23 Buy $2.28 32,134 $73,265.52 4,829,412 SEC Form 4
PERCEPTIVE ADVISORS LLC ATHA Director10% Owner Dec 27 '23 Buy $2.44 409,598 $999,419.12 5,239,010 SEC Form 4
PERCEPTIVE ADVISORS LLC ATHA Director10% Owner Dec 27 '23 Buy $2.38 163,954 $390,210.52 5,402,964 SEC Form 4